Ironwood Pharmaceuticals
IRWD
4.70
-0.01
-0.21%
Ironwood Pharmaceuticals
US · IRWD
#3609 by market cap
4.70
-0.01
-0.21%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
More Money In The Bank For Ironwood Pharmaceuticals Insiders Who Divested US$1.3mSimply Wall St · 2026/11/9
-
Ironwood Pharmaceuticals Raises 2026 View To Rev $485M-$510M IRWDDow Jones · 2026/11/5
-
Company notice
Ironwood Pharmaceuticals | 10-Q: Quarterly reportSEC · 2026/11/6
-
Company notice
Ironwood Pharmaceuticals | SCHEDULE 13G: OthersSEC · 2026/11/10
-
Company notice
Ironwood Pharmaceuticals | 8-K: Current reportSEC · 2026/11/5
-
Rating change
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Maintains Target Price $5Market Newswire · 2026/5/6
-
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Announces Target Price $6Market Newswire · 2026/11/6
-
Rating change
Citizens JMP Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Raises Target Price to $10Market Newswire · 2026/2/26
-
Rating change
Ironwood Pharmaceuticals Raised to Market Outperform From Market Perform by CitizensDow Jones · 2026/1/5
-
Rating change
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy RatingMarket Newswire · 2026/7/16
-
Rating change
Citizens JMP Upgrades Ironwood Pharmaceuticals(IRWD.US) to Buy Rating, Announces Target Price $8Market Newswire · 2026/1/5
-
Rating change
Ironwood Pharmaceuticals Analyst RatingsBenzinga · 2026/1/5
-
Rating change
Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Raises Target Price to $5Market Newswire · 2026/1/5
-
Rating change
Analysts' Top Healthcare Picks: Ironwood Pharma (IRWD), Sionna Therapeutics, Inc. (SION)TipRanks · 2026/5/14
-
Rating change
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)TipRanks · 2025/11/26
-
Company notice
Ironwood Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC · 2026/11/6
-
Rating change
Craig-Hallum Upgrades Ironwood Pharmaceuticals(IRWD.US) to Buy Rating, Raises Target Price to $5.7Market Newswire · 2026/1/5
-
Ironwood Pharmaceuticals Q3 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $133.040M Beat $121.567M EstimateBenzinga · 2026/11/5
-
Company notice
Ironwood Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/14
-
Ironwood Pharmaceuticals Appoints Tammi Gaskins CEO, Effective Jan. 1, 2027Benzinga · 2026/10/16
-
Company notice
Ironwood Pharmaceuticals | SCHEDULE 13G/A: OthersSEC · 2026/8/14
-
Ironwood Pharmaceuticals' Earnings Call Highlights LINZESS SurgeTipRanks · 2026/8/7
-
Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M EstimateBenzinga · 2026/8/6
-
Ironwood Pharmaceuticals Reports Mixed Q2 Results; Raises FY26 OutlookSeeking Alpha · 2026/8/6
-
Company notice
Ironwood Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/9/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.
Ironwood Pharmaceuticals discussion 0 comments